Please assess the completion status of the following clinical trial:

Trial Title: Single Dose Study to Assess Efficacy, Safety and Tolerability of LAS100977 in Asthmatic Patients.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult male and female patients aged 18-70 years (both included).~2. Clinical diagnosis of persistent asthma (according to GINA guidelines 2009 update) for at least 6 months prior to screening.~3. Screening FEV1 value of 60% \< FEV1 ≤ 85% of the predicted normal value.~4. FEV1 reversibility ≥ 12% and an absolute increase of at least 200 ml over baseline value after inhalation of 400µg (four inhalations) of salbutamol.~5. Pre-dose FEV1 value of first treatment period within the range of ± 20% of the FEV1 measured at screening prior to salbutamol inhalation.~6. Patients on a stable dose and regimen~Exclusion Criteria:~1. Current smokers, former smokers within the last 6 months, or ex-smokers with a history of more than 10 pack-years.~2. Patients diagnosed with COPD.~3. Recent Respiratory tract infections within 6 weeks before Screening Visit.~4. Intubation (ever) or hospitalization for longer than 24 hours for the management of an asthma exacerbation within the preceding 6 weeks of the screening visit.~5. Clinically significant respiratory conditions.~6. Clinically significant cardiovascular conditions.~7. Patients unable to properly use a dry powder or pMDI inhaler device or unable to perform acceptable spirometry.~8. Clinically relevant abnormalities laboratory, ECG parameters or physical examination results at the screening evaluation that in the investigator's opinion, preclude study participation.~9. Patients who intend to use any concomitant medication not permitted by this protocol or who have not undergone the required washout period for a particular prohibited medication.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- LAS100977 0.625 μg (Type: EXPERIMENTAL): Single-dose LAS100977 0.625 μg, during double-blind treatment period
- LAS100977 1.25 μg (Type: EXPERIMENTAL): Single-dose LAS100977 1.25 μg, during double-blind treatment period
- LAS100977 2.5 μg (Type: EXPERIMENTAL): Single-dose LAS100977 2.5 μg, during double-blind treatment period
- Salbutamol (Type: ACTIVE_COMPARATOR): Single-dose salbutamol 400 μg, during double-blind treatment period
- Placebo (Type: PLACEBO_COMPARATOR): Placebo to LAS100977, and placebo to salbutamol
- LAS100977 0.313 μg (Type: EXPERIMENTAL): Single-dose LAS100977 0.313 μg, during double-blind treatment period

Based on this trial design, predict the completion outcome and termination type (if applicable).